ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in ASND — Ascendis Pharma A/S
CIK 1164508
BOSTON, MA
Position in ASND
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$20,921,933
+$8,862,517 QoQ
Shares Held
91,470
+50.8% QoQ
Ownership
0.139%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ASND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $1,767,735,657 across 48 Biotechnology names. ASND ranks #16 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
638,950 | $285,316,733 | |
| 2 | INCY |
Incyte Corp
|
2,830,799 | $266,434,801 | |
| 3 | EXEL |
Exelixis, Inc.
|
4,834,625 | $207,357,066 | |
| 4 | GMAB |
Genmab A/S
|
4,975,324 | $133,487,942 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
171,571 | $132,562,617 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
1,918,149 | $123,969,969 | |
| 7 | RPRX |
Royalty Pharma plc
|
2,010,398 | $96,438,792 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
737,859 | $55,405,832 |
All Filings in ASND
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $20,921,933 | 91,470 | Shares | Defined | 2026-05-14 | |
| 2025-09-30 | $12,059,416 | 60,658 | Shares | Defined | 2025-11-13 | |
| 2022-12-31 | $3,568,394 | 29,218 | Shares | Defined | 2023-02-14 | |
| 2022-06-30 | $1,218,240 | 13,105 | Shares | Defined | 2022-08-15 | |
| 2022-03-31 | $237,067 | 2,020 | Shares | Defined | 2022-05-13 | |
| 2020-03-31 | $394,135 | 3,500 | Shares | Defined | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||